Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
suvesitetamab
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Suvesitetamab (SIM0501) is a humanized IgG1 monoclonal antibody targeting Growth Differentiation Factor 15 (GDF15), a stress-induced cytokine belonging to the TGF-beta superfamily. GDF15 is frequently upregulated in various malignancies, including colorectal, lung, and prostate cancers, where it contributes to immune suppression, tumor progression, and cancer-associated cachexia by binding to its receptor, GFRAL. By neutralizing circulating GDF15, suvesitetamab aims to reverse immune evasion and metabolic dysfunction in the tumor microenvironment. Developed by Simcere Pharmaceutical, the agent is currently being investigated in clinical trials as both a monotherapy for advanced solid tumors and in combination with chemotherapy (e.g., trifluridine/tipiracil) for refractory metastatic colorectal cancer.
- Other names
- anti-GDF15 monoclonal antibodyanti-GDF-15 monoclonal antibodyanti-GDF 15 monoclonal antibody
02
Targets
GDF15 (Growth differentiation factor 15)
Beyond the preview
Go deeper on suvesitetamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on suvesitetamab.